## Philipp Enghard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5867225/publications.pdf

Version: 2024-02-01

55	2,521	21 h-index	47
papers	citations		g-index
62	62	62	3312 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Evaluation of SIGLEC1 in the diagnosis of suspected systemic lupus erythematosus. Rheumatology, 2022, 61, 3396-3400.	1.9	5
2	A proteomic survival predictor for COVID-19 patients in intensive care., 2022, 1, e0000007.		28
3	CytoSorb Rescue for COVID-19 Patients With Vasoplegic Shock and Multiple Organ Failure: A Prospective, Open-Label, Randomized Controlled Pilot Study*. Critical Care Medicine, 2022, 50, 964-976.	0.9	45
4	Successful control of <i>Candida auris</i> transmission in a German COVIDâ€19 intensive care unit. Mycoses, 2022, 65, 643-649.	4.0	17
5	CSF2-dependent monocyte education in the pathogenesis of ANCA-induced glomerulonephritis. Annals of the Rheumatic Diseases, 2022, 81, 1162-1172.	0.9	10
6	Intravenous immunoglobulins for treatment of severe COVID-19-related acute encephalopathy. Journal of Neurology, 2022, 269, 4013-4020.	3.6	6
7	Nuclear antigen–reactive CD4+ T cells expand in active systemic lupus erythematosus, produce effector cytokines, and invade the kidneys. Kidney International, 2021, 99, 238-246.	5.2	26
8	Antigenâ€driven PDâ€1 <sup>+</sup> <i>TOX</i> <sup>+</sup> <i>BHLHE40</i> <sup>+</sup> + and PDâ€1 <sup>+</sup> <i>TOX</i> <sup>+</sup> <i>EOMES</i> <sup>+</sup> T lymphocytes regulate juvenile idiopathic arthritis <i>in situ</i> <io>Luropean Journal of Immunology, 2021, 51, 915-929.</io>	2.9	24
9	High rates of long-term renal recovery in survivors of coronavirus disease 2019–associated acute kidney injury requiring kidney replacement therapy. Kidney International, 2021, 99, 1021-1022.	5.2	30
10	Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study. Infection, 2021, 49, 703-714.	4.7	27
11	Critical Illness and Systemic Inflammation Are Key Risk Factors of Severe Acute Kidney Injury in Patients With COVID-19. Kidney International Reports, 2021, 6, 905-915.	0.8	22
12	Point-of-care lung ultrasound in COVID-19 patients: inter- and intra-observer agreement in a prospective observational study. Scientific Reports, 2021, 11, 10678.	3.3	27
13	Long-term effects of COVID-19 on kidney function. Lancet, The, 2021, 397, 1806-1807.	13.7	6
14	Differences between Human and Mouse IgM Fc Receptor (FcµR). International Journal of Molecular Sciences, 2021, 22, 7024.	4.1	9
15	A time-resolved proteomic and prognostic map of COVID-19. Cell Systems, 2021, 12, 780-794.e7.	6.2	125
16	Sodium Thiosulfate Reduces Acute Kidney Injury in Patients Undergoing Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy with Cisplatin: A Single-Center Observational Study. Annals of Surgical Oncology, 2021, , 1.	1.5	12
17	ASO Visual Abstract: Sodium Thiosulfate Reduces Acute Kidney Injury in Patients Undergoing Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy with Cisplatin—A Single CenterÂObservationalÂStudy. Annals of Surgical Oncology, 2021, 28, 698-699.	1.5	О
18	Identification and Validation of IFI44 as Key Biomarker in Lupus Nephritis. Frontiers in Medicine, 2021, 8, 762848.	2.6	18

#	Article	IF	CITATIONS
19	Imlifidase as novel treatment strategy in anti-neutrophil cytoplasmic antibody–induced pulmonary-renal syndrome. Kidney International, 2021, 100, 1344-1345.	5.2	5
20	Establishment of an extracorporeal cardio-pulmonary resuscitation program in Berlin – outcomes of 254 patients with refractory circulatory arrest. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2020, 28, 96.	2.6	10
21	O36â€Low-dose IL-2 therapy modulates lymphocyte subsets that are involved in the regulation of germinal-centre reactions in patients with SLE. , 2020, , .		O
22	Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus. New England Journal of Medicine, 2020, 383, 1149-1155.	27.0	178
23	Identification and characterization of antigen-specific CD4+ T cells targeting renally expressed antigens in human lupus nephritis with two independent methods. Scientific Reports, 2020, 10, 21312.	3.3	9
24	CytoResc – "CytoSorb―Rescue for critically ill patients undergoing the COVID-19 Cytokine Storm: A structured summary of a study protocol for a randomized controlled trial. Trials, 2020, 21, 577.	1.6	24
25	Deep Phenotyping of Urinary Leukocytes by Mass Cytometry Reveals a Leukocyte Signature for Early and Non-Invasive Prediction of Response to Treatment in Active Lupus Nephritis. Frontiers in Immunology, 2020, 11, 256.	4.8	18
26	Identification of Amino Acid Residues in Human IgM Fc Receptor (FcÂ $\mu$ R) Critical for IgM Binding. Frontiers in Immunology, 2020, 11, 618327.	4.8	11
27	Kidney transplant monitoring by urinary flow cytometry: Biomarker combination of T cells, renal tubular epithelial cells, and podocalyxin-positive cells detects rejection. Scientific Reports, 2020, 10, 796.	3.3	20
28	IL-2 Therapy Diminishes Renal Inflammation and the Activity of Kidney-Infiltrating CD4+ T Cells in Murine Lupus Nephritis. Cells, 2019, 8, 1234.	4.1	26
29	Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. Lancet Rheumatology, The, 2019, 1, e44-e54.	3.9	53
30	Prophylactic inhibition of soluble epoxide hydrolase delays onset of nephritis and ameliorates kidney damage in NZB/W F1 mice. Scientific Reports, 2019, 9, 8993.	3.3	7
31	Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study. Rheumatology, 2017, 56, 1618-1626.	1.9	49
32	06.08 Low-dose il-2 therapy in refractory sle: results from a single centre phase i/iia clinical trial. , 2017, , .		1
33	Mapping urinary chemokines in human lupus nephritis: Potentially redundant pathways recruit CD4 <sup>+</sup> and CD8 <sup>+</sup> T cells and macrophages. European Journal of Immunology, 2017, 47, 180-192.	2.9	26
34	What is the clinical significance of anti-Sm antibodies in systemic lupus erythematosus? A comparison with anti-dsDNA antibodies and C3. Clinical and Experimental Rheumatology, 2017, 35, 598-606.	0.8	18
35	Neutropenic Sepsis in the ICU: Outcome Predictors in a Two-Phase Model and Microbiology Findings. Critical Care Research and Practice, 2016, 2016, 1-9.	1.1	2
36	Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2016, 75, 1407-1415.	0.9	303

#	Article	IF	Citations
37	Flow Cytometry of Urinary Leukocytes and Lymphocytes as a Biomarker of Renal Disease., 2016,, 327-345.		O
38	The cellular signature of urinary immune cells in Lupus nephritis: new insights into potential biomarkers. Arthritis Research and Therapy, 2015, 17, 94.	3.5	48
39	Simplified lung ultrasound protocol shows excellent prediction of extravascular lung water in ventilated intensive care patients. Critical Care, 2015, 19, 36.	5.8	140
40	Flow Cytometry of Urinary Leukocytes and Lymphocytes as a Biomarker of Renal Disease., 2015, , 1-19.		0
41	Weak diagnostic performance of troponin, creatine kinase and creatine kinase-MB to diagnose or exclude myocardial infarction after successful resuscitation. International Journal of Cardiology, 2014, 173, 216-221.	1.7	15
42	Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response. Annals of the Rheumatic Diseases, 2014, 73, 277-283.	0.9	60
43	Impaired thymic function and CD4+ T lymphopenia, but not mannose-binding lectin deficiency, are risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients. Transplant Immunology, 2013, 28, 159-163.	1.2	20
44	IFN $\hat{l}\pm$ and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2013, 72, 1639-1645.	0.9	115
45	Unmasking of autoreactive CD4 T cells by depletion of CD25 regulatory T cells in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2011, 70, 2176-2183.	0.9	15
46	Class switching and consecutive loss of dsDNAâ€reactive B1a B cells from the peritoneal cavity during murine lupus development. European Journal of Immunology, 2010, 40, 1809-1818.	2.9	45
47	Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 204-209.	7.1	180
48	CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients. Arthritis and Rheumatism, 2009, 60, 199-206.	6.7	137
49	Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2009, 60, 2083-2093.	6.7	101
50	Autoregulation of Th1-mediated inflammation by <i>twist1 </i> . Journal of Experimental Medicine, 2008, 205, 1889-1901.	8.5	96
51	In Vitro and In Vivo Activation Induces BAFF and APRIL Expression in B Cells. Journal of Immunology, 2007, 179, 5947-5957.	0.8	118
52	Induction of Pathogenic Anti-dsDNA Antibodies Is Controlled on the Level of B Cells in a Non-Lupus Prone Mouse Strain. Journal of Clinical Immunology, 2006, 26, 86-95.	3.8	3
53	Intravenous Injection of a D1 Protein of the Smith Proteins Postpones Murine Lupus and Induces Type 1 Regulatory T Cells. Journal of Immunology, 2004, 173, 5835-5842.	0.8	220
54	Soluble Fc Receptor for IgM in Sera From Subsets of Patients With Chronic Lymphocytic Leukemia as Determined by a New Mouse Monoclonal Antibody. Frontiers in Immunology, $0, 13, .$	4.8	2

#	Article	lF	CITATIONS
55	Urinary CD8+HLA-DR+ T Cell Abundance Non-invasively Predicts Kidney Transplant Rejection. Frontiers in Medicine, 0, 9, .	2.6	2